SCHEMBL2735319

SCHEMBL2735319

Cc1ccc(NC(=O)c2nc[nH]c2C(=O)NC2=NC3C=CC=CC3N2C)c(C)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.46
KMT2A Q03164 6/20 0.45
ALDH1A1 P00352 6/20 0.45
KDM4E B2RXH2 5/20 0.45
MEN1 O00255 5/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
GAA P10253 3/20 0.44
USP2 O75604 1/20 0.42
CYP1A2 P05177 2/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C19 P33261 1/20 0.41
TDP1 Q9NUW8 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
POLB P06746 1/20 0.41
MAPK1 P28482 1/20 0.41
HTT P42858 1/20 0.41
HSD17B10 Q99714 1/20 0.41
HPGD P15428 2/20 0.40
LMNA P02545 1/20 0.40
XBP1 P17861 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL217146 0.75 MAPT (0.52) MAPTKMT2AALDH1A1KDM4EMEN1
SCHEMBL4105577 0.74 GAA (0.55) MAPTKMT2AALDH1A1KDM4EMEN1
SCHEMBL214147 0.74 GAA (0.51) MAPTKMT2AALDH1A1KDM4EMEN1
SCHEMBL216597 0.73 MAPT (0.54) MAPTKMT2AALDH1A1KDM4EMEN1
SCHEMBL2735284 0.71 MAPT (0.60) MAPTKMT2AALDH1A1KDM4EMEN1
SCHEMBL14222343 0.70 MAPT (0.50) MAPTKMT2AALDH1A1KDM4EMEN1
SCHEMBL213157 0.69 MAPT (0.80) MAPTKMT2AALDH1A1KDM4EMEN1
SCHEMBL216151 0.69 MAPT (0.58) MAPTKMT2AALDH1A1KDM4EMEN1
SCHEMBL2759942 0.69 NPC1 (0.54) MAPTKMT2AALDH1A1KDM4EMEN1
SCHEMBL14222699 0.68 MAPT (0.78) MAPTKMT2AALDH1A1KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088767-B2 JAK-2 modulators and methods of use EXELIXIS, INC. (US) 2012-01-03 US disclosed
US-20100136136-A1 JAK-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2010-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100136136-A1 JAK-2 Modulators and Methods of Use JAK2, JAK1, JAK3 MAPT 2138/4885KMT2A 437/4885ALDH1A1 4295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.